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Background: Patients with type 2 diabetes mellitus (T2DM) present subclinical left ventricular systolic and/or
diastolic dysfunction (LVD). Dipeptidyl peptidase-4 (DPP4) inactivates peptides that possess cardioprotective actions.
Our aim was to analyze whether the activity of circulating DPP4 is associated with echocardiographically defined
LVD in asymptomatic patients with T2DM.
Methods: In this cross-sectional study, we examined 83 T2DM patients with no coronary or valve heart disease and
59 age and gender-matched non-diabetic subjects. Plasma DPP4 activity (DPP4a) was measured by enzymatic assay
and serum amino-terminal pro-brain natriuretic peptide (NT-proBNP) was measured by enzyme-linked
immunosorbent assay. LV function was assessed by two-dimensional echocardiographic imaging, targeted M-mode
recordings and Doppler ultrasound measurements. Differences in means were assessed by t-tests and one-way
ANOVA. Associations were assessed by adjusted multiple linear regression and logistic regression analyses.
Results: DPP4a was increased in T2DM patients as compared with non-diabetic subjects (5855 ± 1632 vs 5208 ± 957
pmol/min/mL, p < 0.05). Clinical characteristics and echocardiographic parameters assessing LV morphology were
similar across DPP4a tertiles in T2DM patients. However, prevalence of LVD progressively increased across
incremental DPP4a tertiles (13%, 39% and 71%, all p < 0.001). Multivariate regression analysis confirmed the
independent associations of DPP4a with LVD in T2DM patients (p < 0.05). Similarly, multiple logistic regression
analysis showed that an increase of 100 pmol/min/min plasma DPP4a was independently associated with an
increased frequency of LVD with an adjusted odds ratio of 1.10 (95% CI, 1.04 to 1.15, p = 0.001).
Conclusions: An excessive activity of circulating DPP4 is independently associated with subclinical LVD in T2DM
patients. Albeit descriptive, these findings suggest that DPP4 may be involved in the mechanisms of LVD in T2DM.
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Diabetic cardiomyopathy is a common but frequently
unrecognized pathological process already present in
asymptomatic patients with type 2 diabetes mellitus
(T2DM) [1]. The left ventricle (LV) of these patients is
characterized by an excessive growth that progresses
from a normal functional state to asymptomatic LV dys-
function (LVD) [2,3]. In fact, the prevalence of subclin-
ical LVD in patients with T2DM has been shown to vary
from 25% to 60% in different studies [4-6]. Both subclin-
ical LV diastolic dysfunction (LVDD) and subclinical LV
systolic dysfunction (LVSD) have been described in the
earliest phases of diabetic cardiomyopathy [7-9]. Import-
antly, recent studies demonstrate that subclinical LVD
progress over 5 years in patients with T2DM despite
improved glycemic control [10]. This may explain that
T2DM is associated with increased risk of new-onset
heart failure (HF) [11].
Dipeptidyl peptidase-4 (DPP4) is a membrane glyco-
protein with serine peptidase activity located on the sur-
face of various cell types, that may also exist in plasma
and other body fluids as a soluble form lacking the cyto-
plasmic and transmembrane domains [12]. DPP4 is widely
known for its role in regulation of glycemia through catab-
olism of the incretin glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide 1 (GLP-1),
responsible for glucose-dependent insulin secretion from
the pancreas [13]. A number of observations suggest that
GLP-1 may influence the cardiovascular system [14] and
exert direct cardiac protective actions through the inter-
action with its receptor localized in cardiac cells [15,16].
In this regard, a number of experimental evidences sug-
gest that DPP4 inhibitors may provide cardioprotective
actions beyond their glucose lowering effect [17]. For in-
stance, it has been reported that DPP4 inhibition prevents
LVD and myocardial remodeling in diabetic and non-
diabetic animals exhibiting elevated DPP4 cardiac activity
[18,19]. Interestingly, increased plasma DPP4a has been
found to be associated with LVD in animals [19,20] and
patients [18,19] with HF.
Since there is no available data concerning the activity
of circulating DPP4 (DPP4a) and subclinical LVD in
patients with T2DM, the aim of this study was to investi-
gate whether plasma DPP4a is associated with echocardio-
graphic parameters assessing subclinical LVDD and/or
LVSD in these patients.
Methods
Study population
Eighty-three consecutive patients of Caucasian origin,
aged >30 years, affected by T2DM, and evaluated at the
University of Navarra Clinic between March 2004 and
August 2005, were considered for inclusion in this retro-
spective cross-sectional study. The presence of diabeteswas re-evaluated according to the American Diabetes
Association criteria [21] (glycated haemoglobin [HbA1c] ≥
6.5% or fasting glucose ≥ 126 mg/dl or 2 h plasma glu-
cose ≥ 200 mg/dl during an OGTT or use of hypoglycemic
medication). All of them were free from clinically apparent
cardiovascular disease. Coronary and valve heart disease
were excluded by electrocardiographic and echocardio-
graphic evaluation at rest, and by exercise/scintigraphy/
echo-stress test.
Fifty-nine age- and sex-matched Caucasian patients
coming to the University of Navarra Clinic for a routine
medical work-up were included as controls. None of them
presented medical history of DM or clinically apparent
cardiovascular disease.
According to institutional guidelines, all participants
gave written informed consent to participate. The
study was carried out in accordance with the Helsinki
Declaration and the Ethical Committee of the University
of Navarra Clinic approved it.
Definitions
Concomitant hypertension was defined as systolic blood
pressure (SBP) of ≥ 140 mmHg and/or diastolic blood
pressure (DBP) of ≥ 90 mmHg and/or the presence of
previous chronic antihypertensive treatment. Hyperchol-
esterolemia was diagnosed if the fasting serum total
cholesterol was ≥ 200 mg/dL and hypertriglyceridemia
was diagnosed if serum triglyceride levels were ≥ 150
mg/dL. Obesity was defined as body mass index (BMI) ≥
30 kg/m2. Estimated glomerular filtration rate (GFR) was
determined using the abbreviated Modification of Diet
in Renal Disease (MDRD) equation and the urinary
albumin-to-creatine ratio was measured. Chronic kidney
disease (CKD) was diagnosed if GFR < 60 ml/min/1.73 m2
and/or microalbuminuria was present defined as albumin-
to-creatinine ratio between 30 and 300 mg/g.
Echocardiographic study
Two-dimensional echocardiographic imaging, targeted
M-mode recordings and Doppler ultrasound measure-
ments were obtained in each patient. LV end-diastolic
and systolic volumes (LVEDV and LVESV, respectively),
interventricular septum thickness (IVST), posterior wall
thickness (PWT) and relative wall thickness (RWT) were
calculated as previously reported [22]. RWT > 0.42 was
considered indicative of LV concentric remodeling [23].
LVEDV and LVESV were indexed by body surface area
(BSA) (LVEDVi and LVESVi, respectively). LV mass index
(LVMI) was calculated by dividing LVM by BSA. The
presence of LV hypertrophy (LVH) was established when
LVMI was above 115 g/m2 in men and above 95 g/m2 in
women in accordance with the American Society of
Echocardiography’s Guidelines [23]. The value of LVM
directly measured from echocardiograms was divided by
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LVM as previously described [22] and LVM was expressed
as a percentage of predicted, representing the excess rela-
tive to the “compensatory” value (i.e. 100% of predicted).
Inappropriate LVM was defined as more than 128% of the
predicted value as previously described [22]. LV growth
was established if LV concentric remodeling and/or LV
hypertrophy and/or inappropriate LVM were present.
Two-dimensional estimation of left atrial volume (LAV)
was performed at LV end-systole. LAV was indexed to
body surface area (LAVi). LA enlargement was defined as
LAVi ≥ 29 mL/m2 [23].
The following pulsed Doppler measurements of the
mitral flow were obtained: maximum early transmitral
flow velocity in diastole (E), maximum late transmitral
velocity flow in diastole (A), the deceleration time of the
early mitral filling wave (DT), and isovolumic relaxation
time (IVRT). Tissue Doppler imaging of the lateral
mitral annulus was used for measuring the early (e’)
and late (a’) mitral annulus velocities throughout the car-
diac cycle. Echocardiography evidence of LVDD was
established if E/e’ ratio >15. If E/e’ was between 8-15,
values of e’ < 9 cm/s and mitral inflow E/A ratio age-
corrected abnormal values [24] were considered. In that
case, the presence of at least two abnormal measurements
was taken into account in order to increase the likelihood
of LVDD diagnosis following the European Society of
Cardiology’s Guidelines [25].
LV stroke work was calculated as the product of stroke
volume and end-systolic pressure as previously described
[22]. As a measure of contractility, LV stroke index (LVSWi)
was calculated as LV stroke work divided by LVEDV, as pre-
viously described [26]. LVEF and subendocardial fractional
shortening (FS) were calculated as previously reported [22].
Midwall fractional shortening (MFS) was calculated in ac-
cordance with the American Society of Echocardiography’s
Guidelines [23]. Circumferential end-systolic stress (cESS)
was calculated as previously described [22], to correct MFS
(cESS corrected-MFS). mESS was calculated as previously
reported [22], and corrected by the LVESVi (mESS/
LVESVi). Evidence of LVSD was determined if LVEF < 50%.
If LVEF was between 50-55%, LVSD was considered
if MFS was lower than 15% in women and 14% in men
following the American Society of Echocardiography’s
Guidelines [23]. Finally, evidence of LVD was considered
if either LVDD and/or LVSD were present.
Biochemical determinations
Venous blood samples were withdrawn from the left
antecubital vein at the time of the clinical studies and
stored at -40°C. Plasma DPP4a was measured in duplicate
by using the DPP4-Glo™ Protease Assay (Promega). A ref-
erence standard curve was measured in each different run
by using a purified DPP4 enzyme (BPS Bioscience) withknown activity. DPP4a was measured in the absence or
the presence of valine pyrrolidide, a specific DPP4 inhibi-
tor, to test the specificity of the enzymatic assay. In our
samples, valine pyrrolidide inhibited the assayed activity
by >95%. The intra-assay and inter-assay coefficients of
variation were 1.86% and 9.95%, respectively and the sen-
sitivity of the technique has been established as the detec-
tion of the cleaving activity of 0.5 ng of recombinant
DPP4.
Amino-terminal pro-brain natriuretic peptide (NT-
proBNP) was measured in serum samples by ELISA
(Biomedica Gruppe). The sensitivity was 5 fmol of NT-
proBNP/mL. The inter-assay and intra-assay coefficients
of variation were lower than 10%.
Statistical analysis
Continuous variables were reported as mean values ±
one standard deviation or, if not normally distributed,
as median and interquartile range, whereas categorical
variables were reported as numbers and percentages.
Differences between non-diabetic subjects and diabetic
patients were tested by Student’s t-test for unpaired data
once normality was demonstrated (Kolmogorov-Smirnov
test); otherwise, a nonparametric test (Mann-Whitney U-
test) was used. Differences in continuous variables be-
tween more than two groups were tested by one-way
ANOVA followed by a Student-Newman-Keuls test once
normality was checked (Shapiro-Wilks test); otherwise,
the nonparametric Kruskal-Wallis test followed by a
Mann-Whitney U test (adjusting the α-level by Bonferroni
inequality) was used. Categorical variables were analysed
by the χ2 test or Fisher’s exact test when necessary. Mul-
tiple regression analyses were performed to assess the in-
dependent relationship between circulating DPP4a and
echocardiographic parameters of LV systolic and diastolic
function after adjustment for relevant covariates: age, sex,
HbA1c, SBP, presence of CKD, anti-hypertensive treat-
ment and anti-diabetic treatment. Logistic regression
analysis was performed to derive odds ratio and 95% con-
fidence intervals adjusted for covariates. Statistical signifi-
cance was defined as two-sided p < 0.05. The statistical
analysis was done using the SPSS software (15.0 version;
SPSS Inc., Chicago, Illinois, USA).
Results
Clinical characteristics
The demographic and clinical parameters evaluated in
non-diabetic subjects and in patients with T2DM are
presented in Table 1. As compared with non-diabetics,
T2DM patients exhibited higher body mass index (BMI),
and decreased diastolic and mean blood pressure values.
As expected, the percentage of HbA1c and the fasting
glucose levels in blood were significantly increased in
T2DM patients as compared with non-diabetic subjects.
Table 1 Demographic and clinical parameters in the
population according to the presence or absence of
diabetes
Parameters Non-diabetic
subjects
Diabetic
patients
p value
(n = 59) (n = 83)
Age (years) 63.6 ± 9.5 65.4 ± 8.4 0.214
Male/female (n, %) 33/26, 56/44 52/31, 63/37 0.264
BMI (Kg/m2) 28 ± 4.3 29.8 ± 5 0.049
SBP (mmHg) 143 ± 22 139 ± 21.4 0.333
DBP (mmHg) 80 (72-90) 75 (70-80) 0.002
MBP (mmHg) 102 ± 13.9 96.5 ± 12.3 0.016
PP (mmHg) 62.3 ± 17.5 64 ± 19.4 0.605
HbA1c (%) 5.3 (5.1-5.4) 6.7 (5.9-7.5) <0.001
Fasting glucose (mg/dL) 92 (87-95) 115 (101-138) <0.001
Comorbidities, (n, %)
Hypertension 41, 70 68, 82 0.064
Hypertriglyceridemia 8, 14 18, 22 0.158
Hypercholesterolemia 34, 58 23, 28 <0.001
Obesity 18, 30 39, 47 0.049
CKD 5, 8.5 15, 18 0.115
Treatment, (n, %)
Antidiabetic agents
Metformin 0, 0 25, 30
Sulfonylureas 0, 0 18, 22
Other oral anti-diabetic drugs 0, 0 22, 27
Insulin 0, 0 23, 28
Anti-hypertensive agents
ACEi/ARAs 16, 28 49, 59 <0.001
Diuretics 6, 10 20, 24 0.030
Ca2 + -antagonists 10, 17 19, 23 0.274
Beta-blockers 5, 9 20, 24 0.014
Other pharmacological agents
Statins 14, 24 48, 58 <0.001
Anti-coagulants 0, 0 14, 16
Anti-aggregants 14, 24 44, 53 <0.001
BMI means body mass index; SBP, systolic blood pressure; DBP, diastolic blood
pressure; MBP, mean blood pressure; PP, pulse pressure; HbA1c, glycosylated
haemoglobin; CKD, chronic kidney disease; ACEi, angiotensin converting
enzyme inhibitor; ARA, angiotensin II type 1 receptor antagonist. Obesity was
defined as BMI ≥ 30 kg/m2 and CKD was diagnosed if the estimated
glomerular filtration rate was < 60 ml/min/1.73m2 and/or microalbuminuria
was present defined as an albumin-to-creatinine ratio between 30 and 300
mg/g. Values are expressed as mean ± SD or median (interquartile range), and
categorical variables as numbers and percentages.
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both groups although the prevalences of hypercholester-
olemia and obesity were lower and higher, respectively,
in patients with T2DM than in non-diabetic subjects. As
expected, more patients in the diabetic group wereunder treatment with cardiovascular drugs (including
anti-hypertensive medications) than in the non-diabetic
group.
Echocardiographic parameters
Table 2 shows the echocardiographic parameters assessed
in the population according to the presence or absence of
T2DM. Compared with non-diabetic subjects, T2DM pa-
tients exhibited higher prevalence of LV concentric re-
modeling and inappropriate LVM. The prevalence of LVH
and LA enlargement was similar in the 2 groups of sub-
jects. In addition, parameters assessing LV diastolic and
systolic function were altered in T2DM patients as com-
pared with non-diabetic subjects. Therefore, the preva-
lence of LVDD and LVSD was higher in patients with
T2DM than in non-diabetic subjects. Finally, the preva-
lence of LVD (considered as the presence of LVDD and/or
LVSD) was increased in T2DM patients as compared with
non-diabetic subjects (44.6% vs 6.8%, p < 0.001).
Biochemical parameters
Plasma DPP4a was higher in T2DM patients as com-
pared with non-diabetic subjects (5208 ± 957 vs 5855 ±
1632 pmol/min/mL, p < 0.05). In addition, compared with
non-diabetic subjects, patients with T2DM exhibited
higher levels of NT-proBNP (234 ± 136 vs 348 ±180 fmol/
mL, p < 0.01).
Plasma DPP4a and clinical and echocardiographic
characteristics in patients with T2DM
Table 3 shows the clinical features of patients with
T2DM classified according to tertiles of plasma DPP4a.
Age, gender, BMI, blood pressure, HbA1c, fasting glu-
cose, comorbidities and treatment were similar among
the three groups of patients.
As shown in Table 4, parameters of LV and LA
morphology did not change across the three groups of
T2DM patients categorized according to plasma DPP4a.
Interestingly, T2DM patients with the highest values
of plasma DPP4a (third tertile) exhibited increased
values of E/e’ ratio as compared with patients showing
lower DPP4a (first tertile) (Figure 1A). In addition,
T2DM patients in the second and third DPP4a tertiles
showed lower values of E/A ratio than patients in the
first DPP4a tertile (Figure 1B). Moreover, T2DM patients
in the third tertile of DPP4a had lower values of LVSWi
(Figure 1C), LVEF (Figure 1D) and MFS (Figure 1E) as
compared with patients in the first tertile. In accordance
with these differences, the prevalence of both LVDD and
LVSD progressively increased across tertiles of plasma
DPP4a in diabetic patients (Figure 2). Finally, the preva-
lence of LVD was 13%, 39% and 71% in patients from
the first, second and third tertiles of plasma DPP4a, re-
spectively (χ2 = 16.2, p < 0.001).
Table 2 Echocardiographic parameters in the population
according to the absence or presence of diabetes
Parameters Non-diabetic
subjects
Diabetic
patients
p value
(n = 59) (n = 83)
LV Morphology
LVEDVindex (mL/m2) 64.9 ± 14.8 63.9 ± 15.3 0.714
LVESVindex (mL/m2) 22.5 ± 7.8 23.1 ± 8.6 0.695
IVSTd (mm) 10 (8-11) 10 (9-12) 0.033
PWTd (mm) 10 (9-12) 11 (10-12) 0.448
RWT 0.40 ± 0.06 0.44 ± 0.08 0.026
Prevalence of LV concentric
geometry (n, %)
21, 36 49, 59 0.008
LVM/BSA (g/m2) 94.3 (80.1-126) 105 (87.8-127) 0.228
Prevalence of LVH (n, %) 27, 46 37, 44 0.510
Observed/predicted LVM (%) 118 ± 31 133 ± 34.7 0.025
Prevalence of inappropriate
LVM (n, %)
16, 27 43, 52 0.007
LA Morphology
LA long-axis (cm) 4.9 ± 0.7 5.2 ± 0.8 0.021
LA minor-axis (cm) 3.7 ± 0.7 3.8 ± 0.7 0.385
LA ap (cm) 3.6 ± 0.7 3.7 ± 0.8 0.448
LA volume index (mL/m2) 19.2 (14.6-25.1) 18.1 (14.9-27.6) 0.863
Prevalence of LA
enlargement (n,%)
7, 12 19, 23 0.093
LV diastolic function
E (cm/s) 74.6 ± 15.2 78.1 ± 20.1 0.353
A (cm/s) 84.3 ± 18.9 88.4 ± 19.5 0.241
E/A ratio 0.91 ± 0.23 0.83 ± 0.16 0.042
IVRT (ms) 110 (90-121) 100 (90-120) 0.113
DT (ms) 220 (180-258) 220 (190-260) 0.811
e' (cm/s) 9.1 ± 2.5 8.3 ± 2.4 0.151
E/e' 8.5 (6.6-10.5) 9.3 (7.6-12) 0.046
a' (cm/s) 10.4 ± 2.8 11.4 ± 3 0.088
e'/a' 0.74 (0.58-1.2) 0.66 (0.54-0.78) 0.028
Prevalence of LV diastolic
dysfunction (n, %)
3, 5.2 30, 36.6 <0.001
LV systolic function
LVSWi (g/cm-2) 85.2 ± 13.8 78.9 ± 15.6 0.017
LVEF (%) 65.1 ± 6.7 62.2 ± 6.2 0.010
FS (%) 35.9 ± 5.1 33.5 ± 4.8 0.007
MFS (%) 16.8 ± 3 15.8 ± 2.6 0.045
cESS (kdyne/cm2) 142 (117-176) 139 (118-175) 0.854
mESS (kdyne/cm2) 77.3 ± 18.5 73.1 ± 20.2 0.213
Table 2 Echocardiographic parameters in the population
according to the absence or presence of diabetes
(Continued)
cESS-MFS (%) 99.9 ± 18 94.1 ± 14.8 0.042
mESS/LVESVi (107 dyne/cm3) 3.3 (2.4-4.8) 2.9 (2.1-2.9) 0.071
Prevalence of LV systolic
dysfunction (n, %)
4, 6.8 17, 20.5 0.019
LV means left ventricular; LVEDVi, LV end-diastolic volume index; LVESVi, LV
end-systolic volume index; IVSTd, interventricular septum thickness in diastole;
PWTd, posterior wall thickness in diastole; RWT, relative wall thickness; LVM,
LV mass; BSA, body surface area; LVH, left ventricular hypertrophy; LA, left
atrial; E, maximum early transmitral velocity in diastole; A, maximum late
transmitral velocity in diastole; IVRT, isovolumic relaxation time; DT,
deceleration time; e’, early mitral annulus velocity; a’, late mitral annulus
velocity; LVSWi, LV stroke work index; LVEF, LV ejection fraction; FS,
subendocardial fractional shortening; MFS, midwall fractional shortening; cESS,
circumferential end-systolic stress; mESS, meridional end-systolic stress. Values
are expressed as mean ± SD or median (interquartile range), and categorical
variables as numbers and percentages.
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tertiles of DPP4 activity (first to third DPP4 tertiles: 338 ±
196 vs 345 ± 180 vs 372 ± 191 fmol/mL, p = 0.823).
Study of associations
Associations between plasma DPP4a and parameters of
LV diastolic and systolic function were analyzed in T2DM
patients by multivariate linear regression analysis. After
adjusting for potential confounding factors (age, gender,
HbA1c, SBP, presence of CKD, anti-hypertensive treat-
ment and anti-diabetic treatment), plasma DPP4a was dir-
ectly correlated with the E/e’ ratio (β = 0.307, p = 0.036).
In addition, an inverse correlation was detected between
plasma DPP4a and the E/A ratio independently of gender,
HbA1c, SBP, presence of CKD, anti-hypertensive treat-
ment and anti-diabetic treatment (β = -0.295, p = 0.036).
However, the multiple regression analysis evaluating the
association between plasma DPP4a and the E/A ratio ren-
dered a non-significant β coefficient after adjustment for
age. Furthermore, plasma DPP4a was inversely associated
with LVSWi (β = -0.210, p = 0.025), LVEF (β = -0.291, p =
0.040) and MFS (β = -0.365, p = 0.008) independently of
all the considered potential confounding factors (age, gen-
der, HbA1c, SBP, presence of CKD, anti-hypertensive
treatment and anti-diabetic treatment).
No associations of NT-proBNP levels with parameters
assessing LV systolic and diastolic function were identi-
fied in T2DM patients.
Multiple logistic regression analysis confirmed the pre-
vious observations since an increase of 100 pmol/min/
mL in plasma DPP4a was significantly associated with a
higher risk of LVDD (Table 5) and of LVSD (Table 6) in
T2DM patients, independently of all the above consid-
ered confounding factors. Thus, an increase of 100
pmol/min/min plasma DPP4a was independently associ-
ated with an increased frequency of LVD with an ad-
justed odds ratio of 1.10 (95% CI, 1.04 to 1.15, p =
Table 3 Demographic and clinical parameters according to tertiles of circulating DPP4 activity in diabetic patients
Parameters DPP4 (pmol/min/mL)
p value<5060 5060-6208 >6208
Age (years) 65 ± 9.1 66.2 ± 7.1 64.7 ± 9.7 0.836
Male/female (%) 59/41 68/32 61/39 0.657
BMI (Kg/m2) 32 ± 6.4 28.5 ± 4.5 29.4 ± 4.5 0.086
SBP (mmHg) 140 ± 17 136 ± 23.8 141 ± 23.9 0.767
DBP (mmHg) 80 (70-80) 70 (60-80) 75 (70-80) 0.300
MBP (mm Hg) 97.8 ± 8 93.6 ± 13.8 97.8 ± 13.4 0.395
PP (mmHg) 63.3 ± 17.5 64.1 ± 18.4 64.3 ± 23.2 0.984
HbA1c (%) 6.5 (6.1-7.4) 6.5 (5.9-7.2) 6.9 (6-7.9) 0.555
Fasting glucose (mg/dL) 112 (100-129) 113 (106-169) 117 (109-171) 0.265
Comorbidities, (n, %)
Hypertension 22, 82 22, 79 24, 85 0.997
Hypertriglyceridemia 5, 19 6, 21 7, 25 0.811
Hypercholesterolemia 4, 15 9, 32 10, 36 0.440
Obesity 16, 60 9, 32 14, 50 0.230
CKD 6, 22 5, 17 4, 14 0.409
Treatment (n, %)
Antidiabetic agents
Metformin 9, 33 4, 14 12, 43 0.064
Sulfonylureas 7, 26 7, 26 4, 14 0.199
Other oral anti-diabetic drugs 5, 19 7, 26 10, 36 0.418
Insulin 6, 22 7, 25 10, 36 0.664
Anti-hypertensive agents
ACEi/ARAs 17, 63 15, 53 17, 61 0.634
Diuretics 6, 22 7, 25 7, 25 0.938
Ca2 + -antagonists 3, 11 9, 32 7, 25 0.104
Beta-blockers 7, 26 7, 25 6, 21 0.888
Other pharmacological agents
Statins 15, 55 18, 64 15, 57 0.824
Anti-coagulants 5, 19 4, 14 5, 19 0.910
Anti-aggregants 15, 56 15, 53 14, 50 0.902
BMI means body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; PP, pulse pressure; HbA1c, glycosylated
haemoglobin; CKD, chronic kidney disease; ACEi, angiotensin converting enzyme inhibitor; ARA, angiotensin II type 1 receptor antagonist. Values are expressed as
mean ± SD or median (interquartile range), and categorical variables as numbers and percentages.
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tertile of plasma DPP4a had an adjusted odds ratio for
LVD of 8.18 (95% CI, 2.19 to 30.6, p = 0.002).
Discussion
The main findings of this study are the following: (1) the
activity of circulating DPP4 is abnormally increased in
patients with T2DM; (2) increased activity of circulating
DPP4 is independently associated with asymptomatic
LVDD and LVSD in T2DM patients; and (3) T2DM pa-
tients with increased activity of circulating DPP4 exhibita higher risk of presenting LVD independently of the
presence of confounding factors.
In accordance with previous studies [27-29], we show
that plasma DPP4a is increased in patients with T2DM.
Although it has been reported that plasma DPP4a is as-
sociated with HbA1c levels in T2DM patients [27,30],
no associations were found between plasma DPP4a and
parameters assessing glucose metabolism in this study.
On the other hand, although experimental [20] and clin-
ical [31,32] data suggest that overweight and obesity
may influence circulating DPP4 levels and activity, no
Table 4 Echocardiographic parameters according to tertiles of circulating DPP4 activity in diabetic patients
Parameters DPP4 (pmol/min/mL)
p value<5060 5060-6208 >6208
LV Morphology
LVEDVindex (mL/m2) 63.7 ± 13 66.4 ± 12 63.9 ± 17 0.794
LVESVindex (mL/m2) 20.8 ± 6.6 22.9 ± 9.5 25.4 ± 7.7 0.080
IVSTd (mm) 10 (9-12) 11(9-13) 10 (9-12) 0.450
PWTd (mm) 10 (9-12) 11 (10-12) 11 (9.3-12) 0.095
RWT 0.42 ± 0.06 0.46 ± 0.05 0.42 ± 0.09 0.086
Prevalence of LV concentric geometry (n, %) 15, 55 20, 71 14, 50 0.128
LVM/BSA (g/m2) 94.6 (81-132) 112 (94.6-134) 110 (84-131) 0.201
Prevalence of LVH (n, %) 10, 37 16, 57 11, 40 0.294
Observed/predicted LVM (%) 124 ± 27.9 132 ± 25.4 134 ± 30.6 0.535
Prevalence of inappropriate LVM (n, %) 13, 48 16, 57 14, 50 0.932
LA Morphology
LA long-axis (cm) 5.4 ± 0.7 5.1 ± 0.9 5.3 ± 0.8 0.443
LA minor-axis (cm) 4 ± 0.7 3.7 ± 0.7 3.9 ± 0.8 0.605
LA ap (cm) 3.8 ± 0.6 3.5 ± 0.9 3.8 ± 0.9 0.424
LA volume index (mL/m2) 20.3 (16-29.3) 17 (14.7-23.7) 20.7 (13.2-33) 0.450
Prevalence of LA enlargement (n,%) 7, 26 4, 14 8, 29 0.442
LV means left ventricular; LVEDVi, LV end-diastolic volume index; LVESVi, LV end-systolic volume index; IVSTd, interventricular septum thickness in diastole; PWTd,
posterior wall thickness in diastole; RWT, relative wall thickness; LVM, LV mass; BSA, body surface area; LVH, left ventricular hypertrophy; LA, left atrial. Values are
expressed as mean ± SD or median (interquartile range), and categorical variables as numbers and percentages.
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http://www.cardiab.com/content/12/1/143associations of plasma DPP4a with BMI or obesity were
found in the current study. Finally, although previous
studies have suggested that some oral anti-diabetic
agents other than gliptins (e.g., metformin) may alter the
activity of circulating DPP4 [33], other studies have
failed to reproduce the findings [34]. In our study,
plasma DPP4a was independent of the treatment with
oral antidiabetic drugs, including metformin, and insulin.
Therefore, the mechanisms involved in an excessive
activity of circulating DPP4 in T2DM patients from our
study remain to be elucidated.
Findings from previous studies show association of the
activity of circulating DPP4 with LVD in HF. In fact,
experimental studies have shown that increased
plasma DPP4a is associated with LVD in animals with
HF [19,20]. There are also clinical observations relating an
excess of plasma DPP4a with LVD in HF patients, namely
in those with diabetes mellitus [18,19]. On the other hand,
it has been shown that genetically-induced deficiency of
DPP4 or pharmacological inhibition of DPP4 that reduce
plasma DPP4a also result in improved LV function. In
particular, this has been demonstrated in normoglucemic
swine models of ischemia-reperfusion [35] and overpacing-
induced HF [36], in normoglucemic rodent models of HF
induced by pressure overload [37], radiofrequency LV abla-
tion [19] or myocardial infarction [38], as well as in
insulin-resistant obese rodent models [39] and in diabeticrodent models of myocardial infarction-induced HF
[40,41]. Collectively, these data suggest that an exces-
sive activity of circulating DPP4 may be related with
advanced symptomatic LVD. In this conceptual frame-
work, our study demonstrates for the first time that
plasma DPP4a is independently associated with both
LVDD and LVSD in asymptomatic T2DM patients, thus
suggesting that an excessive activity of circulating DPP4
can be involved in early subclinical LVD in T2DM.
The question arises of which mechanisms link the ac-
tivity of circulating DPP4 with LVD. One possibility is
that DPP4 inactivates circulating peptides that possess
cardioprotective actions, including GLP-1, BNP, and
peptide YY [42,43]. However, the majority of these sub-
strates serve as pharmacological targets in vitro, but few
have been shown to be endogenous, physiological sub-
strates (defined as peptides whose endogenous circulat-
ing level of intact versus N-terminally cleaved forms is
altered after reduction or elimination of DPP4 activity
in vivo) [44]. An alternative possibility is that increased
activity of circulating DPP4 coincides with increased
activity of cardiac DPP4, thus allowing for direct detri-
mental actions of the enzyme on the myocardium. This
possibility is based on two observations [18]. First, a direct
correlation between DPP4a measured in blood from the
antecubital vein and that measured in blood from the
coronary sinus has been reported in humans. Second,
Figure 1 Distribution of echocardiographic parameters assessing left ventricular diastolic and systolic function in patients with T2DM
categorized according to plasma DPP4 activity levels. Box plots show the 5th and 95th (vertical lines), 25th and 75th (boxes) and 50th
(horizontal line) percentile values for E/e’ ratio (panel A), E/A ratio (panel B), stroke work corrected by left ventricular (LV) end-diastolic volume
(LVEDV) (panel C), LV ejection fraction (LVEF) (panel D) and midwall fractional shortening (MFS) (panel E).
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http://www.cardiab.com/content/12/1/143myocardial DPP4 overactivity was found to be associated
with reduced myocardial availability of stromal cell-
derived factor 1α and impaired angiogenesis and fibrosis
in diabetic rats with HF.
The third finding of this study is that plasma DPP4a is
an independent risk factor for subclinical LVD in T2DM
patients. In fact, an increase of 100 pmol/min/min
plasma DPP4a was independently associated with 10%
increase in the risk of subclinical LVD in T2DM pa-
tients. It has been recently shown that the likelihood of
subclinical LVD in these patients increases independ-
ently with age, HbA1c, and treatment with metformin
[5]. Interestingly, the greater risk of subclinical LVD as-
sociated with plasma DPP4a was independent of these
factors. On the other hand, although increased NT-
proBNP has been proposed as a risk factor for subclin-
ical LVD in T2DM patients [45,46], no association wasfound in this study between NT-proBNP levels and sub-
clinical LVD. Therefore, plasma DPP4a emerges as a
useful variable to predict early-stage LVD in T2DM pa-
tients without known cardiac disease. The potential clin-
ical relevance of this possibility is given by the high
prevalence of subclinical LVD in patients with T2DM
(e.g. almost 45% in our study). Furthermore, considering
the high risk for subclinical LVD to evolve to overt HF in
T2DM patients [10,11], plasma DPP4a may be also useful
as a therapeutic guide to prevent the deterioration of LV
function in these patients.
Limitations
Some limitations of the current study must be recognized.
First, data here presented are relevant to a selected sample
from a single centre. Second, the cross-sectional design
of the study does not allow for causal interpretation
Figure 2 Prevalence of left ventricular diastolic dysfunction and left ventricular systolic dysfunction in patients with T2DM categorized
according to plasma DPP4 activity levels. Grey bars show the prevalence of left ventricular diastolic dysfunction (LVDD: χ2 = 8.82, p = 0.012)
and black bars show the prevalence of left ventricular systolic dysfunction (LVSD: χ2 = 7.62, p = 0.022).
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http://www.cardiab.com/content/12/1/143of the relationships found. Third, unfortunately, we could
not determine concentrations of active (GLP-1 [7-36]), as
samples were not collected in tubes with a DPP4 inhibitor.
Therefore, future studies should establish how much of
plasma DPP4a is related to GLP-1 (7-36) concentration
and whether the active GLP-1 peptide may be influencing
the associations found between plasma DPP4a and
LVD. Fourth, whereas LVSD was assessed using con-
ventional Doppler echocardiography, in accordance with
the American Society of Echocardiography’s Guidelines
[23], we are aware that more refined methods (e.g. speckle
tracking) would allow for a more detailed characterization
of LV contraction. Fifth, it must be recognized that in-
clusion of untreated diabetics and patients treated withTable 5 Multiple logistic regression analysis (dependent
variable, presence of left ventricular diastolic
dysfunction)
Significant
correlates
Units of increase Odds ratio 95% CI p value
DPP4 100 pmol/min/mL 1.05 1.01-1.09 0.027
Not significant
correlates
Age 1 year 1.09 0.99-1.19 0.069
Male gender 0.40 0.10-1.55 0.183
HbA1c 1% 1.09 0.62-1.91 0.776
SBP 1 mm Hg 1.01 0.97-1.04 0.741
CKD 0 = no; 1 = yes 2.30 0.34-15.8 0.396
Anti-hypertensive
treatment
0 = no; 1 = yes 0.68 0.14-3.38 0.637
Anti-diabetic
treatment
0 = no; 1 = yes 2.01 0.40-10.6 0.413
DPP4 means dipeptidyl peptidase-4; HbA1c, glycosylated haemoglobin;
SBP, systolic blood pressure; CKD, chronic kidney disease. Data are expressed
as odds ratio and 95% confidence interval.different classes of drugs may have confounded the find-
ings here obtained and their interpretation. However, as
mentioned above, the pharmacological treatment did not
seem to affect the associations of plasma DPP4a with pa-
rameters of LV function.
In summary, findings from the current study show
that the activity of circulating DPP4 is associated with
subclinical LVD in T2DM patients with no coronary or
valve heart disease. Albeit preliminary and descriptive in
nature, these results set the stage for further experimen-
tal studies aimed to test the potential involvement of an
excess of DPP4 in the pathogenesis of LVD in diabetes.
Furthermore, adequate prospective studies should be
considered in order to explore the usefulness of plasma
DPP4a as a diagnostic biomarker and a therapeuticTable 6 Multiple logistic regression analysis (dependent
variable, presence of left ventricular systolic dysfunction)
Significant
correlates
Units of increase Odds ratio 95% CI p value
DPP4 100 pmol/min/mL 1.10 1.01-1.21 0.032
SBP 1 mm Hg 0.91 0.84-0.99 0.022
Not significant
correlates
Age 1 year 1.11 0.92-1.34 0.264
Male gender 4.45 0.37-54 0.241
HbA1c 1% 0.77 0.24-2.47 0.659
CKD 0 = no; 1 = yes 2.64 0.08-83.4 0.581
Anti-hypertensive
treatment
0 = no; 1 = yes 2.86 0.10-80.6 0.538
Anti-diabetic
treatment
0 = no; 1 = yes 0.30 0.01-7.31 0.449
DPP4 means dipeptidyl peptidase-4; HbA1c, glycosylated haemoglobin;
SBP, systolic blood pressure; CKD, chronic kidney disease. Data are expressed
as odds ratio and 95% confidence interval.
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http://www.cardiab.com/content/12/1/143target for HF in patients with T2DM. These aspects
can be particularly relevant taking into account that,
although some meta-analysis indicate that inhibition
of DPP4a with gliptins may decrease the risk of HF
and other adverse cardiovascular events in T2DM pa-
tients [47-49], it has been recently reported that
DPP4 inhibition with saxagliptin is associated with in-
creased risk of hospitalization for HF in T2DM pa-
tients [50].
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